University of Oxford’s COVID-19 vaccine ‘highly effective’ at treating virus, trials show

NEWS IN BRIEF: A COVID-19 vaccine being developed by the University of Oxford and British pharmaceutical company AstraZeneca was found to have an average efficacy rate of 70% following a large-scale trial. The trial involved two separate dosing regimens, one which showed a 90% efficacy rate, and the other with 62%. Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said the results “show that we have an effective vaccine that will save many lives.”